Experts note the biggest impacts to derm in 2015
It’s that time of year again. We’re looking back on what made the biggest impacts on dermatology in 2015. Dermatology Times asked dermatologists around the United States: In your opinion, what was the most interesting or valuable development in dermatology in the last year? This is what they had to say. (You’ll see many agreed on one new treatment.)
Submental fat and injectable melanoma treatment
Christine C. Kim, M.D., Dermatology Institute & Skin Care Center, Santa Monica, Calif.: There were two very different, but both groundbreaking, dermatologic developments in 2015, which exemplifies the very unique nature of dermatology as both a medical and a cosmetic specialty. On the cosmetic front, the FDA approved Kybella (deoxycholic acid, Allergan) for improvement in the appearance of moderate to severe submental fullness via a series of subcutaneous injections. Finally there is an alternative to more invasive techniques such as liposuction to improve the contour of your profile.
Just this past October, the FDA approved the drug Imlygic (talimogene laherparepvec, Amgen), a genetically-modified oncolytic herpes virus therapy, for the treatment of recurrent, unresectable melanoma lesions. Imlygic is injected directly into melanoma lesions of the skin or lymph nodes, where it replicates inside cancer cells causing them to rupture and die. It is novel because it is the first oncolytic viral therapy of its kind approved by the FDA and will hopefully pave the way for other cancer-fighting drugs using viruses.